We commenced the year by reporting a solid 2023 Full-Year performance.
Jean-Marc Huët was nominated as the new Chair of Lonza for election at the Annual General Meeting 2024 in May.
We announced the appointment of Wolfgang Wienand as our new Chief Executive Officer.
We announced the issuance of a CHF 1 billion straight bond.
We signed renewable energy certificate agreements in the US, supporting our goal to source 100% of electricity from renewable sources where available by 2025.
We launched an AI-enabled route scouting service to address the growing complexity of small molecule active pharmaceutical ingredients (APIs).
We welcomed our new Chair, Jean-Marc Huët, following a shareholder vote at our Annual General Meeting.
We welcomed our new Chief Executive Officer, Wolfgang Wienand.
We communicated our Half-Year 2024 financial results.
The Board of Directors nominated Juan Andres and Eric Drapé for election as Independent Board Members at the Annual General Meeting 2025.
We signed a long-term commercial supply agreement with Vertex for CASGEVY®, the world’s first approved gene-edited therapy using CRISPR/ Cas9 technology for the treatment of sickle cell disease and beta-thalassemia.
We completed an expansion of our Microbial manufacturing facility in Visp (CH).
We inaugurated the Innovaform™ Accelerator – our new Center of Excellence in Colmar (FR) – to collaborate with pharmaceutical customers on formulation and encapsulation projects.
We successfully completed the acquisition of the Genentech large-scale biologics site in Vacaville (US) from Roche, welcoming around 800 new colleagues to Lonza.
The Board of Directors nominated David Meline for election as an Independent Board Member at the Annual General Meeting 2025.
We announced a long-term extension of our collaboration with a major global biopharmaceutical partner for the commercial-scale manufacture of ADCs.
We completed the expansion of our new drug product services facility in Basel (CH).
We announced plans to invest in two new bioconjugation manufacturing suites in Visp (CH), which will double our multipurpose capacity for the launch and commercial supply of bioconjugates.
We announced the completion of the first GMP product batch supported from the recently completed next-generation mammalian manufacturing facility in Portsmouth (US).
We outlined our new One Lonza strategy and organizational structure, including the plan to exit the Capsules & Health Ingredients business at the appropriate time and in the best interest of shareholders and stakeholders.
